For patients with stage 2 or greater bladder cancer, care transitions linked with treatment delay
the ONA take:
According to a new study published in the Journal of Urology, researchers have found patients with stage 2 or higher urothelial carcinoma who underwent a care transition were more likely to experience a delay in treatment of 3 months or greater.
For the study, researchers sought to investigate whether changing hospitals between diagnosis and therapy for patients with muscle invasive bladder cancer would experience a delay in timely treatment. They identified 22,251 patients with stage 2 or greater urothelial carcinoma treated between 2003 and 2010 from the National Cancer Database.
Patients were considered to have underwent a care transition if they experienced a change in hospital between diagnosis of cancer and treatment with radical cystectomy or the initiation of neoadjuvant chemotherapy. Of all patients identified, 14.2% experienced a treatment delay of 3 months or more.
This proportion increased from 13.5% between 2003 and 2006 to 14.8% between 2007 and 2010 (P = 0.01). Of the patients who underwent a care transition, 19.4% experienced a treatment delay of 3 months or greater versus 10.7% who were diagnosed and treated at the same facility. The authors suggest that expediting care transitions at the time of hospital referral may improve the quality of care for patients with muscle invasive bladder cancer.
Patients with stage 2 or higher urothelial carcinoma who underwent care transition more likely to experience a delay in treatment.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|